Asthma and COVID-19 risk: a systematic review and meta-analysis.

Sunjaya, AP; Allida, SM; Di Tanna, GL; Jenkins, CR

Asthma and COVID-19 risk: a systematic review and meta-analysis.

Sunjaya, AP Allida, SM Di Tanna, GL Jenkins, CR

Permalink

Publisher:: European Respiratory Society
Publication Type:: Journal Article
Citation:: European Respiratory Journal, 2022, 59, (3), pp. 1-16
Issue Date:: 2022-03

Recently Added

	Filename	Description	Size
	Asthma and COVID-19 risk a systematic review and meta-analysis. .pdf	Published version	814.53 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is new to OPUS and is not currently available.

Full metadata record

Field	Value	Language
dc.contributor.author	Sunjaya, AP
dc.contributor.author	Allida, SM
dc.contributor.author	Di Tanna, GL
dc.contributor.author	Jenkins, CR
dc.date.accessioned	2022-10-26T03:58:07Z
dc.date.available	2021-08-02
dc.date.available	2022-10-26T03:58:07Z
dc.date.issued	2022-03
dc.identifier.citation	European Respiratory Journal, 2022, 59, (3), pp. 1-16
dc.identifier.issn	0905-9180
dc.identifier.issn	1399-3003
dc.identifier.uri	http://hdl.handle.net/10453/162714
dc.description.abstract	BACKGROUND: Individual case series and cohort studies have reported conflicting results in people with asthma on the vulnerability to and risk of mortality from coronavirus disease 2019 (COVID-19). RESEARCH QUESTION: Are people with asthma at a higher risk of being infected or hospitalised or poorer clinical outcomes from COVID-19? METHODS: A systematic review and meta-analysis based on five main databases including the World Health Organization COVID-19 database between 1 December 2019 and 11 July 2021 on studies with a control (non-asthma) group was conducted. Prevalence and risk ratios were pooled using Sidik-Jonkman random-effects meta-analyses. FINDINGS: 51 studies with an 8.08% (95% CI 6.87-9.30%) pooled prevalence of people with asthma among COVID-19 positive cases. The risk ratios were 0.83 (95% CI 0.73-0.95, p=0.01) for acquiring COVID-19; 1.18 (95% CI 0.98-1.42, p=0.08) for hospitalisation; 1.21 (95% CI 0.97-1.51, p=0.09) for intensive care unit (ICU) admission; 1.06 (95% CI 0.82-1.36, p=0.65) for ventilator use; and 0.94 (95% CI 0.76-1.17, p=0.58) for mortality for people with asthma. Subgroup analyses by continent revealed a significant difference in risk of acquiring COVID-19, ICU admission, ventilator use and death between the continents. INTERPRETATION: The risk of being infected with severe acute respiratory syndrome coronavirus 2 was reduced compared to the non-asthma group. No statistically significant differences in hospitalisation, ICU admission and ventilator use were found between groups. Subgroup analyses showed significant differences in outcomes from COVID-19 between America, Europe and Asia. Additional studies are required to confirm this risk profile, particularly in Africa and South America, where few studies originate.
dc.format	Electronic-Print
dc.language	eng
dc.publisher	European Respiratory Society
dc.relation.ispartof	European Respiratory Journal
dc.relation.isbasedon	10.1183/13993003.01209-2021
dc.rights	info:eu-repo/semantics/restrictedAccess
dc.subject	11 Medical and Health Sciences, 1116 Medical Physiology
dc.subject.classification	Respiratory System
dc.subject.mesh	Asthma
dc.subject.mesh	COVID-19
dc.subject.mesh	Hospitalization
dc.subject.mesh	Humans
dc.subject.mesh	Intensive Care Units
dc.subject.mesh	SARS-CoV-2
dc.subject.mesh	Asthma
dc.subject.mesh	COVID-19
dc.subject.mesh	Hospitalization
dc.subject.mesh	Humans
dc.subject.mesh	Intensive Care Units
dc.subject.mesh	SARS-CoV-2
dc.subject.mesh	Humans
dc.subject.mesh	Asthma
dc.subject.mesh	Hospitalization
dc.subject.mesh	Intensive Care Units
dc.subject.mesh	COVID-19
dc.subject.mesh	SARS-CoV-2
dc.title	Asthma and COVID-19 risk: a systematic review and meta-analysis.
dc.type	Journal Article
utslib.citation.volume	59
utslib.location.activity	England
utslib.for	11 Medical and Health Sciences
utslib.for	1116 Medical Physiology
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/IMPACCT
utslib.copyright.status	recently_added	*
pubs.consider-herdc	false
dc.date.updated	2022-10-26T03:58:03Z
pubs.issue	3
pubs.publication-status	Published
pubs.volume	59
utslib.citation.issue	3

Abstract:

BACKGROUND: Individual case series and cohort studies have reported conflicting results in people with asthma on the vulnerability to and risk of mortality from coronavirus disease 2019 (COVID-19). RESEARCH QUESTION: Are people with asthma at a higher risk of being infected or hospitalised or poorer clinical outcomes from COVID-19? METHODS: A systematic review and meta-analysis based on five main databases including the World Health Organization COVID-19 database between 1 December 2019 and 11 July 2021 on studies with a control (non-asthma) group was conducted. Prevalence and risk ratios were pooled using Sidik-Jonkman random-effects meta-analyses. FINDINGS: 51 studies with an 8.08% (95% CI 6.87-9.30%) pooled prevalence of people with asthma among COVID-19 positive cases. The risk ratios were 0.83 (95% CI 0.73-0.95, p=0.01) for acquiring COVID-19; 1.18 (95% CI 0.98-1.42, p=0.08) for hospitalisation; 1.21 (95% CI 0.97-1.51, p=0.09) for intensive care unit (ICU) admission; 1.06 (95% CI 0.82-1.36, p=0.65) for ventilator use; and 0.94 (95% CI 0.76-1.17, p=0.58) for mortality for people with asthma. Subgroup analyses by continent revealed a significant difference in risk of acquiring COVID-19, ICU admission, ventilator use and death between the continents. INTERPRETATION: The risk of being infected with severe acute respiratory syndrome coronavirus 2 was reduced compared to the non-asthma group. No statistically significant differences in hospitalisation, ICU admission and ventilator use were found between groups. Subgroup analyses showed significant differences in outcomes from COVID-19 between America, Europe and Asia. Additional studies are required to confirm this risk profile, particularly in Africa and South America, where few studies originate.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/162714